In-vitro Toxicology Testing Market by Testing Approaches (In Silico, In Chemico, and Others), Application (Metabolic, Toxicokinetic, Bioanalytical, Skin, Liver and Kidney, Lung, and Others), Offerings [Assays(Screening Assays, Genotoxicity Assays, Eye Irritation Equivalency Assays, Skin Irritation and Corrosion Equivalency Assays, Skin Lightening Assay, Advanced 3D Tissue Models, Advanced 3D Tissue Models, Custom Mechanistic Assays, Others), Platform and Solutions, Services, and Others], End User (Pharmaceutical & Biopharmaceutical Companies, Cosmetic Companies, Chemical Companies, and Others): Global Market Size Estimates and Forecast (2022–2030)

Code: BMIRE00025853 | Pages: 100 | Industry: Biotechnology | Date: Sep 2022 | Type: Global

The market crossed US$ 12.17 billion mark in 2022 and is expected to hit US$ 33.42 billion by 2030, recording a CAGR of 13.5 % during the forecast period.

Metabolic segment is expected to hold the largest market share in the forecasted period.

According to Diabetology & Metabolic Syndrome article, the prevalence of the metabolic syndrome ranges from 20 to 25% in the adult population and 0 to 19.2% in children globally in 2020; but it can reach almost 80% in type 2 diabetes patients. In vitro drug metabolism studies are being conducted using models of human drug metabolism that are performed using in vitro comparative studies, utilizing tissue or enzymes from human and experimental species. The increasing regulation of the pharmaceutical industry has resulted in wasting time and costs associated with the drug development. This has resulted the usage of human tissue or enzymes in vitro that can be utilized in a cost-effective and timely manner to target the clinical studies. For example, in vitro studies can potentially examine drug-drug interactions and the effect of environmental agents, ethnic background, gender, and genetics on the metabolism of a drug. In vitro models for drug metabolism can include hepatocytes or subcellular fractions of the liver such as microsomes, cytosol, or S9 fraction, depending on the goal of the research study. Such factors has assisted the growth of metabolism segment in the recent years and is expected to continue a similar trend over the forecast period.

Within the report, the market is segmented into testing approaches, application, offerings, end user, and geography. By testing approaches, the market is further segmented into in silico, in chemico, and others. On the application, the market is segmented into metabolic, toxicokinetic, bioanalytical, skin, liver & kidney, lung, and others. By offerings, the market is categorized into assays, platform & solutions, services, and others. Based on assays, the market is categorized into screening assays, genotoxicity assays, eye irritation equivalency assays, skin irritation & corrosion equivalency assays, skin lightening assay, advanced 3d tissue models, custom mechanistic assays, and others. Based on end user, the market is segmented into pharmaceutical & biopharmaceutical companies, cosmetic companies, chemical companies, and others. Geographically, the market is subsegmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

Development of predictive toxicology is expected to propel the overall market growth

The rising need for the toxicological assessment of chemicals and using fewer animals and less-expensive tools has strongly assisted the development of predictive toxicology and structure-based approaches. Predictive toxicology plays an important role in the assessment of toxicity of chemicals and the drug development process. To make predictive toxicology methods effective in nature, the field needs access to the largest possible base of previous toxicology findings, which also needs to be interoperable and comparable in nature. Databases containing safety records of chemicals, their actions, genetic implications, lethal dose information, various formulations, and toxicogenomic studies will help to promote the efficient use of alternative methods of toxicology testing. The data sharing on a common platform will help in understanding the different effects of toxic substances and the potential effects of it on a human being. Thus, the development of public and computable toxicology datasets based on standardized and controlled strategies will support data management & validation, model building, and reporting, including regulatory reporting and alternative testing submission requirements, leading to new scientific advancements in a mechanistically based predictive toxicology. This will contribute to the growth of the in-vitro toxicology testing market.

Get more information on this report :

Pharmaceutical & biopharmaceutical companies captured the highest share in 2022

The in-vitro toxicology testing helps pharmaceutical & biopharmaceutical companies in identification of compound viability in preclinical phase of drug development or novel product development. In addition, notable advancements in in-vitro toxicology assays to evaluate drug product safety coupled with assessment of the effects of pharmaceuticals on cells and tissues are expected to increase revenue generation of pharmaceutical companies.

Recent strategic developments in in-vitro toxicology testing market

The in-vitro toxicology testing market has undergone several significant developments, and a few of these have been mentioned below:

  • In March 2021, the Institute for In Vitro Sciences (IIVS) and the Research Institute for Fragrance Materials (RIFM) collaborated to develop a non-animal (in vitro) test designed to assess respiratory allergens. In this collaboration, IIVS used human precision-cut lung slices (hPCLS) to elucidate molecular pathways pertained with respiratory sensitizers that are distinct from those of respiratory irritants and skin sensitizers.

The In-vitro toxicology testing market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Agilent Technologies, IONTOX (LifeNet Health Sciences), Bio-Rad Laboratories, Inc., Covance (Labcorp Drug Development), Eurofins Scientific, Charles River Laboratories, Sigma-Aldrich Corporation, Intertek Group plc., SGS SA, EVOTEC, Creative Biolabs, and Aragen Bioscience are among the prominent players operating in the market.

Target audience for the report:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Government bodies, such as regulating authorities
  • Research institutes, organizations, and consulting companies
  • Academic Institutes
  • Chemical Companies
  • Dermatology Organizations

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Testing Approach:
    • In Silico
    • In Chemico
    • Others
  • Application
    • Metabolic
    • Toxicokinetic
    • Bioanalytical
    • Skin
    • Liver and Kidney
    • Lung
    • Others
  • Offering:
    • Assays
      • Screening Assays
      • Genotoxicity Assays
      • Eye Irritation Equivalency Assays
      • Skin Irritation and Corrosion Equivalency Assays
      • Skin Lightening Assay
      • Advanced 3D Tissue Models
      • Custom Mechanistic Assays
      • Others
    • Platform and Solutions
    • Services
    • Others
  • End User:
    • Pharmaceutical & Biopharmaceutical Companies
    • Cosmetic Companies
    • Chemical Companies
    • Others 
  • Region
    • North America
      • US
      • Canada
      • Mexico
    • Europe
    • Asia Pacific (APAC)
    • Middle East & Africa
    • South & Central America

Companies profiled:

    • Agilent Technologies
    • IONTOX (LifeNet Health Sciences)
    • Bio-Rad Laboratories, Inc.
    • Covance (Labcorp Drug Development)
    • Eurofins Scientific
    • Charles River Laboratories.
    • Sigma-Aldrich Corporation
    • Intertek Group plc
    • SGS SA
    • EVOTEC
    • Creative Biolabs
    • Aragen Bioscience
  •  
  • Agilent Technologies
  • IONTOX (LifeNet Health Sciences)
  • Bio-Rad Laboratories, Inc.
  • Covance (Labcorp Drug Development)
  • Eurofins Scientific
  • Charles River Laboratories.
  • Sigma-Aldrich Corporation
  • Intertek Group plc
  • SGS SA
  • EVOTEC
  • Creative Biolabs
  • Aragen Bioscience
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500